Mölndal, Sweden

Lars Johan Andreas Ulander

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Lars Johan Andreas Ulander: Innovator in Pharmaceutical Chemistry

Introduction

Lars Johan Andreas Ulander is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic use. With a total of 5 patents to his name, Ulander has established himself as a key figure in the industry.

Latest Patents

Among his latest innovations are pyrazole derivatives that serve as 5-lipoxygenase activating protein (FLAP) inhibitors. These compounds are designed to treat and prevent clinical conditions, including cardiovascular diseases (CVD). The applications detail their utility in therapeutic methods, pharmaceutical compositions, and processes for preparing these novel compounds.

Career Highlights

Ulander is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work focuses on advancing medical treatments through innovative chemical solutions. His expertise in pharmaceutical chemistry has been instrumental in the development of new therapeutic agents.

Collaborations

Ulander has collaborated with esteemed colleagues such as Johan Olof Broddefalk and Kenneth Lars Granberg. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Lars Johan Andreas Ulander is a prominent inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of cardiovascular diseases significantly. His contributions through innovative patents and collaborations continue to advance the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…